Browsing: England

A collaboration between health technology assessment (HTA) bodies in the US, Canada, and England will investigate how non-traditional benefits, like the value of hope and scientific spillover, can inform appraisals and understandings of a product’s value.

Pharming’s Joenja, a treatment for APDS, has been approved for reimbursement in England after NICE reversed its earlier rejection. The EU regulatory review is still ongoing.

A former senior figure at England’s NICE states that advanced therapies for common conditions would not qualify for the usual payment modifiers.